1. Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older 
Koji Kawamura, Shinichi Kako, Shuichi Mizuta, Ken Ishiyama, Jun Aoki, Shingo Yano, Takahiro Fukuda, Naoyuki Uchida, Yukiyasu Ozawa, Tetsuya Eto, Koji Iwato, Heiwa Kanamori, Kaoru Kahata, Tadakazu Kondo, Masashi Sawa, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshinobu Kanda 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 12, Pages (December 2017)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
OS (A, standard risk; B, high risk), DFS (C, standard risk; D, high risk), relapse (E), and NRM (F) in the FB2, FB4, and FM140 groups.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Cumulative incidences of grades II to IV (A) and III to IV (B) acute GVHD and chronic (C) and extensive chronic (D) GVHD in the FB2, FB4, and FM140 groups.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
OS (A, standard-risk AML; B, high-risk AML; C, standard-risk ALL; D, high-risk ALL; E, standard-risk MDS; F, high-risk MDS) in the FB2, FB4, and FM140 groups, classified according to the background disease.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
Cumulative incidence of relapse (A, AML; C, ALL; E, MDS) and NRM (B, AML; D, ALL; F, MDS) in the FB2, FB4, and FM140 groups, classified according to the background disease.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions